In conclusion, our data support a model wherein ongoing inflammation (including hypothalamic gliosis) represents a druggable mechanism implicated in obesity pathogenesis, one that can be ameliorated by NLRP3 inhibition. Here, NLRP3 is linked to obesity disorder.